Cytomegalovirus (CMV) Research Projects

Antibody and viral determinants of protection against CMV infection following gB/MF59 vaccination

gB/MF59 immunization has proven moderately efficacious (~50%) at preventing primary HCMV infection in multiple phase II clinical trials. The goal of this study is to investigate the mechanism of protection of vaccine-elicited antibodies, as well as viral immune evasion thereof.

Sponsored by NIH: R21-AI136556

Immunologic and virologic determinants of congenital Cytomegalovirus transmission and disease in rhesus monkeys

Our goal is to advance congenital CMV vaccine research by defining the key immune responses and viral-host interactions that dictate primary fetal CMV transmission and disease in a highly relevant animal model.  


Sponsored By: NIH: 1P01-AI129859

Use of  a novel nonhuman primate model of congenital CMV for defining protective immunity.

We recently established a highly-relevant nonhuman primate model of congenital CMV

transmission through primary RhCMV infection of seronegative, breeding female rhesus monkeys. We are currently using this model to dissect the role of the maternal adaptive immune system in protection against intrauterine CMV transmission and virus-associated infant sequelae, establishing immunologic targets of a maternal CMV vaccine.


Sponsored By: NIH: DP2-HD075699

Humoral immune correlates of protection against congenital CMV and HSV transmission in HIV-infected women

We are enrolling women with a diagnosis of primary CMV infection during pregnancy. Samples are analyzed to evaluate the protective immune responses.


Spornsored by NIH: 1R21-AI147992

Duke University School of Medicine

2017 Proudly created with